Last 12 months
Inside the activity.
0 purchase rows · 240 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 200 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 31 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2014 Filed Jul 30, 2014 19:01 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 249,700 | $63.03 | $15,738,591.00 |
DisclosureSEC source: 0001209191-14-049518 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,341,104 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.64 to $63.63, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionEmployee stock option 2/06 (right to buy) · Derivative | 1,175 | $0.00 Strike: $56.18 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · derivative · entry 8 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 1,175 shares Expires 2016-02-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionEmployee stock option 2/05 (right to buy) · Derivative | 1,065 | $0.00 Strike: $55.65 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · derivative · entry 7 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 0 Underlying: Common Stock · 1,065 shares Expires 2015-02-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 2,065 | $63.30 | $130,714.50 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 3 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 7,810 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 1,175 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 9,875 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 28, 2014 Filed Jul 30, 2014 20:32 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 1,065 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000135 · wf-form4_140675226363198.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Indirect · by husband Disclosed balance after: 8,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| July 25, 2014 Filed Jul 28, 2014 19:07 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
SaleCommon Stock | 30,000 | $63.90 | $1,917,000.00 |
DisclosureSEC source: 0000059478-14-000131 · wf-form4_140657441526361.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,798 Read SEC document |
| July 25, 2014 Filed Jul 28, 2014 19:16 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
SaleCommon Stock | 10,000 | $63.79 | $637,900.00 |
DisclosureSEC source: 0000059478-14-000133 · wf-form4_140657495079866.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,736 F1 · price: This transaction was executed in multiple trades at prices ranging from $63.72 to $63.84. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 01, 2014 Filed Jul 2, 2014 19:29 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 235,000 | $62.30 | $14,640,500.00 |
DisclosureSEC source: 0001209191-14-045082 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,590,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.02 to $62.545, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 30, 2014 Filed Jun 30, 2014 15:54 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 146 | $58.83 | $8,589.18 |
DisclosureSEC source: 0000059478-14-000124 · wf-form4_140414366071767.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,281 Read SEC document |
| June 25, 2014 Filed Jun 26, 2014 18:23 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 400 | $63.10 | $25,240.00 |
DisclosureSEC source: 0001209191-14-043780 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,825,804 F2 · price: The shares reported in Column 4 were sold at $63.10. Read SEC document |
| June 25, 2014 Filed Jun 26, 2014 18:23 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 244,600 | $62.68 | $15,331,528.00 |
DisclosureSEC source: 0001209191-14-043780 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,826,204 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.07 to $63.06, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| June 20, 2014 Filed Jun 23, 2014 19:01 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 85,600 | $61.95 | $5,302,920.00 |
DisclosureSEC source: 0001209191-14-043080 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,070,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.80 to $62.14, inclusive. Read SEC document |
| June 20, 2014 Filed Jun 23, 2014 19:01 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 144,400 | $61.31 | $8,853,164.00 |
DisclosureSEC source: 0001209191-14-043080 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,156,404 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.79, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| June 20, 2014 Filed Jun 25, 2014 20:28 UTC Amendment |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 85,600 | $61.96 | $5,303,776.00 |
DisclosureSEC source: 0000911916-14-000098 · edgar.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,070,804 F3 · price: This Amendment is being filed to correct the weighted average price reported in Column 4 of Table I in the Form 4 filed on June 23, 2014, which inadvertantly reported the weighted average price as $61.95. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.80 to $62.14, inclusive. Read SEC document |
| June 20, 2014 Filed Jun 25, 2014 20:28 UTC Amendment |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 144,400 | $61.42 | $8,869,048.00 |
DisclosureSEC source: 0000911916-14-000098 · edgar.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,156,404 F1 · price: This Amendment is being filed to correct the weighted average price reported in Column 4 of Table I in the Form 4 filed on June 23, 2014, which inadvertantly reported the weighted average price as $61.31. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.80 to $61.79, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (4) to this Form 4. Read SEC document |
| June 16, 2014 Filed Jun 17, 2014 17:33 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 200,000 | $58.73 | $11,746,000.00 |
DisclosureSEC source: 0001209191-14-041909 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,300,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.51 to $59.13, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 13, 2014 Filed Jan 29, 2015 18:26 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000009 · wf-form5_142255599923302.xml · nonDerivative · entry 5 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 49,102 F1 · ownership.nature: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| June 12, 2014 Filed Jan 29, 2015 18:26 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 944 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000009 · wf-form5_142255599923302.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 529,635 Read SEC document |
| June 09, 2014 Filed Oct 31, 2014 18:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 620 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000176 · wf-form4_141477857451933.xml · nonDerivative · entry 5 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,966 Read SEC document |
| June 05, 2014 Filed Jun 6, 2014 15:59 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 190,000 | $59.53 | $11,310,700.00 |
DisclosureSEC source: 0001209191-14-039484 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,500,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.20 to $59.75, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| June 05, 2014 Filed Oct 31, 2014 18:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 6,475 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000176 · wf-form4_141477857451933.xml · nonDerivative · entry 4 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 534,586 Read SEC document |
| May 30, 2014 Filed May 30, 2014 11:44 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 146 | $58.65 | $8,562.90 |
DisclosureSEC source: 0000059478-14-000115 · wf-form4_140145025640614.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,945 Read SEC document |
| May 29, 2014 Filed May 30, 2014 11:46 UTC |
Walsh Fionnuala MSVP, Global Quality
|
Tax withholdingCommon Stock | 2,584 | $59.70 | $154,264.80 |
DisclosureSEC source: 0000059478-14-000116 · wf-form4_140145037219396.xml · nonDerivative · entry 1 Walsh Fionnuala M · CIK 0001524637 · SVP, Global Quality 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,646 Read SEC document |
| May 21, 2014 Filed May 22, 2014 18:37 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 230,000 | $58.90 | $13,547,000.00 |
DisclosureSEC source: 0001209191-14-036098 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,690,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.66 to $59.09, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 12, 2014 Filed May 13, 2014 13:40 UTC |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 1,700 | $59.14 | $100,538.00 |
DisclosureSEC source: 0000059478-14-000110 · wf-form4_139998842891290.xml · nonDerivative · entry 2 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,180 Read SEC document |
| May 12, 2014 Filed May 13, 2014 13:40 UTC |
TAI JACKSON PDirector
|
PurchaseCommon Stock | 15,457 | $59.19 | $914,899.83 |
DisclosureSEC source: 0000059478-14-000110 · wf-form4_139998842891290.xml · nonDerivative · entry 1 TAI JACKSON P · CIK 0001173275 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,480 F1 · price: This transaction was executed in multiple trades at prices ranging from $59.14 to $59.22. The price reported reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 12, 2014 Filed May 13, 2014 18:06 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 210,000 | $59.33 | $12,459,300.00 |
DisclosureSEC source: 0001209191-14-033232 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,920,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.09 to $59.87, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| May 06, 2014 Filed May 7, 2014 18:43 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 3,600 | $59.50 | $214,200.00 |
DisclosureSEC source: 0001209191-14-031785 · doc4.xml · nonDerivative · entry 2 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,130,804 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.48 to $59.55, inclusive. Read SEC document |
| May 06, 2014 Filed May 7, 2014 18:43 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 186,400 | $58.78 | $10,956,592.00 |
DisclosureSEC source: 0001209191-14-031785 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,134,404 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to $59.45, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4. Read SEC document |
| April 30, 2014 Filed May 2, 2014 15:53 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 141 | $60.86 | $8,581.26 |
DisclosureSEC source: 0000059478-14-000104 · wf-form4_139904598429586.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,799 Read SEC document |
| April 30, 2014 Filed Oct 31, 2014 18:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 435 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000176 · wf-form4_141477857451933.xml · nonDerivative · entry 3 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,061 Read SEC document |
| April 29, 2014 Filed Apr 30, 2014 18:53 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 200,000 | $59.43 | $11,886,000.00 |
DisclosureSEC source: 0001209191-14-029843 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,320,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.28 to $59.66, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| April 29, 2014 Filed Jan 29, 2015 18:33 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
GiftCommon Stock | 85 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-15-000013 · wf-form5_142255639647288.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,155 Read SEC document |
| April 28, 2014 Filed Apr 29, 2014 19:16 UTC |
LILLY ENDOWMENT INC10% owner
|
SaleCommon Stock | 150,000 | $58.64 | $8,796,000.00 |
DisclosureSEC source: 0001209191-14-029653 · doc4.xml · nonDerivative · entry 1 LILLY ENDOWMENT INC · CIK 0000316011 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,520,804 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.18 to $59.14, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4. Read SEC document |
| March 31, 2014 Filed Mar 31, 2014 18:06 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 146 | $58.87 | $8,595.02 |
DisclosureSEC source: 0000059478-14-000092 · wf-form4_139628918007236.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,658 Read SEC document |
| March 13, 2014 Filed Oct 31, 2014 18:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000176 · wf-form4_141477857451933.xml · nonDerivative · entry 2 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,496 Read SEC document |
| March 03, 2014 Filed Sep 8, 2014 16:14 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 58,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000149 · wf-form4_141019288800941.xml · nonDerivative · entry 2 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Indirect · by wife Disclosed balance after: 276,514 F1 · ownership.direct: Reporting person disclaims beneficial ownership of these shares. Read SEC document |
| March 03, 2014 Filed Sep 8, 2014 16:14 UTC |
Rice Derica WEVP-Global Services and CFO
|
GiftCommon Stock | 58,990 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000149 · wf-form4_141019288800941.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 03, 2014 Filed Oct 31, 2014 18:03 UTC |
LECHLEITER JOHN CDirector · Chairman, President and CEO
|
GiftCommon Stock | 17,215 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000176 · wf-form4_141477857451933.xml · nonDerivative · entry 1 LECHLEITER JOHN C · CIK 0001209281 · Director · Chairman, President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 541,929 Read SEC document |
| February 28, 2014 Filed Feb 28, 2014 14:20 UTC |
Alvarez RalphDirector
|
GrantCommon Stock | 155 | $55.25 | $8,563.75 |
DisclosureSEC source: 0000059478-14-000088 · wf-form4_139359722650280.xml · nonDerivative · entry 1 Alvarez Ralph · CIK 0001310215 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,327 Read SEC document |
| February 03, 2014 Filed Feb 4, 2014 20:48 UTC |
Rice Derica WEVP-Global Services and CFO
|
SaleCommon Stock | 16,562 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-14-000072 · wf-form4_139154688113422.xml · nonDerivative · entry 1 Rice Derica W · CIK 0001359067 · EVP-Global Services and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,990 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 13, 2013. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.46 to $53.75. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 03, 2014 Filed Feb 4, 2014 20:48 UTC |
Ricks David ASVP and Pres, Lilly Bio-Meds
|
SaleCommon Stock | 3,086 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000059478-14-000073 · wf-form4_139154689662444.xml · nonDerivative · entry 1 Ricks David A · CIK 0001538604 · SVP and Pres, Lilly Bio-Meds 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,084 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2013. F2 · price: This transaction was executed in multiple trades at prices ranging from $53.89 to $53.90. The price reported reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionRestricted Stock Unit · Derivative | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · derivative · entry 4 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,674 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Tax withholdingCommon Stock | 7,363 | $54.01 | $397,675.63 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · nonDerivative · entry 2 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,736 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:25 UTC |
Conterno Enrique ASr. VP & Pres., Lilly Diabetes
|
Exercise / conversionCommon Stock | 15,674 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000059 · wf-form4_139152754455047.xml · nonDerivative · entry 1 Conterno Enrique A · CIK 0001476151 · Sr. VP & Pres., Lilly Diabetes 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionRestricted Stock Unit · Derivative | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · derivative · entry 6 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,107 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Tax withholdingCommon Stock | 6,627 | $54.01 | $357,924.27 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · nonDerivative · entry 2 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,798 Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Mahony SusanSVP & Pres., Lilly Oncology
|
Exercise / conversionCommon Stock | 14,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000060 · wf-form4_139152756373404.xml · nonDerivative · entry 1 Mahony Susan · CIK 0001463321 · SVP & Pres., Lilly Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,425 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2014 Filed Feb 4, 2014 15:26 UTC |
Peterson Barton RSr. VP, Corp. Affairs & Comm.
|
Exercise / conversionRestricted Stock Unit · Derivative | 7,837 | $0.00 | $0.00 |
DisclosureSEC source: 0000059478-14-000061 · wf-form4_139152758135653.xml · derivative · entry 4 Peterson Barton R · CIK 0001466550 · Sr. VP, Corp. Affairs & Comm. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,837 shares Expires 2014-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.